We have set up this channel to give you convenient access to the latest research in the area of Cancer-associated thrombosis (CAT) by providing a customised feed of abstracts of clinical papers published on PubMed. The combination of search terms providing the feed below is 'cancer AND thrombosis'. This channel is sorted chronologically. To see more information about a given paper, click the ‘Preview Abstract’ button below, and this will reveal an expanded abstract.
BACKGROUND: Compact fibrin clots relatively resistant to lysis are observed in patients at increased risk of venous thromboembolism (VTE) including malignancy. The citrullinated histone H3 (H3Cit) predicts VTE in cancer patients.
OBJECTIVES: We performed a cohort study to investigate whether abnormal clot properties predict cancer diagnosis following unprovoked VTE.
METHODS: In 369 consecutive patients aged <70 years without malignancy detected during routine...
BACKGROUND: Coagulation activation is a hallmark of cancer, and anticoagulants have shown tumour-inhibiting properties. However, recent trials have failed to demonstrate improved survival with low-molecular-weight heparin (LMWH) in cancer populations. This has raised the question of suboptimal adherence as a possible explanation for the lack of benefit. Still, there is no standardised method to directly monitor LMWH in patient plasma. Here, we directly determine LMWH levels...
BACKGROUND: Microvascular invasion (MVI) predicts poor prognosis in patients with hepatocellular carcinoma (HCC). HCC patients with hypercoagulability are prone to develop thrombosis; however, the relationship between preoperative coagulability state, as reflected by the international normalized ratio (INR) level, and MVI remains unclear.
METHODS: From January 2009 to December 2012, HCC patients who underwent R0 liver resection (LR) from four cancer centers entered...
Aging and chronic inflammation are independent risk factors for the development of atherothrombosis and cardiovascular disease. We hypothesized that aging-associated inflammation promotes the development of platelet hyperreactivity and increases thrombotic risk during aging. Functional platelet studies in aged-frail adults and old mice demonstrated that their platelets are hyperreactive and form larger thrombi. We identified TNF- as the key aging-associated proinflammatory...
Nonbacterial thrombotic endocarditis (NBTE) associated with malignancy is rare; its infrequency and similarity to other diagnoses make it a significant diagnostic challenge. A 63-year-old woman on rivaroxaban for prior deep vein thrombosis presented with left upper extremity weakness and left facial droop with imaging demonstrating multiple strokes. Echocardiograms revealed mitral and aortic valve vegetations. The patient was switched to apixaban and started on vancomycin and...
The failure of mechanisms of natural anti-coagulation either due to genetic impairment or due to severe external injuries may result in a condition called thrombosis. This is believed to be the primary cause for a variety of life-threatening conditions such as: heart attack, stroke, pulmonary embolism, thrombophlebitis, and deep venous thrombosis (DVT). The growing number of these incidents requires an alternative anti-coagulant or anti-thrombotic agent that has minimal side...
BACKGROUND: Alcoholism is associated with variable effects on the coagulation system. Therefore, the aim of our study was to analyze the currently unknown association between chronic alcohol consumption and the risk of venous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE).
METHODS: We performed a 2-y (2013-2014) analysis of the American College of Surgeons Trauma Quality Improvement Program database. All trauma patients with an...
BACKGROUND: Although venous thromboembolism (VTE) is a significant complication for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), no validated clinical model predicts VTE in this population. This study aimed to derive and validate a new risk assessment model (RAM) for IMiD-associated VTE.
METHODS: Patients with newly diagnosed MM receiving IMiDs were selected from the SEER-Medicare database (n=2,397) to derive a RAM and then data from...
Venous thromboembolism (VTE) is a growing concern in patients with cancer. Current guidelines recommend that cancer patients with VTE should receive anticoagulation for at least 3-6 months. However, the question as to whether anticoagulants should be continued after 3 to 6 months of treatment remains open. In presence of an active malignancy, physicians should weigh the benefits and burdens of ongoing anticoagulation taking into account the clinical status, patient...
Myocardial infarction, commonly known as heart attack, evolves from the rupture of unstable atherosclerotic plaques to coronary thrombosis and myocardial ischemia-reperfusion injury. A body of evidence supports a close relationship between the alterations following an ischemia-reperfusion injury-induced oxidative stress and platelet activity. Through their critical role in thrombogenesis and inflammatory responses, platelets are fully (totally) implicated from...
ICTHIC Lunchtime Symposium April 2018: Dr Marc Carrier
ICTHIC Lunchtime Symposium April 2018: Alexander Cohen
ICTHIC Lunchtime Symposium April 2018: Dr Florian Langer MD
ICTHIC Lunchtime Symposium April 2018: Dr Luis Jara-Palomares, MN, PhD
Structured Modules in CAT
Nov 21, 2016
Oct 28, 2016
Oct 27, 2016
Sep 29, 2016
This website is intended to provide non-promotional, educational information to an international healthcare professional audience only.
You have indicated that you are not a healthcare professional and therefore, do not have access to this site.Please click here to continue browsing
This website is owned by LEO Pharma.
Cookies by themselves cannot be used to discover the identity of the user, and they do not in any way damage your computer.
We use a Google Analytics cookie, further information can be seen here:: Google Analytics Cookie Usage
The browsers of most computers, smartphones and other web-enabled devices are typically set up to accept cookies. If you wish to amend your cookie preferences for this site or any other websites, you can do this through your browser settings. Your browser's 'help' function will tell you how to do this.
However, please remember that cookies are often used to enable and improve certain functions on our site. If you therefore choose to disable the cookies that we use, this may impact your experience while on www.cathrombosis.com, for example, you may not be able to visit certain areas of the site and you may not receive personalised information.
If you use different devices to view and access the site (e.g. your computer, smartphone, tablet etc.) you will need to ensure that each browser on each device is adjusted to suit your cookie preferences.
For more information on how to disable cookies, visit www.allaboutcookies.org